155 related articles for article (PubMed ID: 11058882)
1. Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes.
Ito M; Shichijo S; Miyagi Y; Kobayashi T; Tsuda N; Yamada A; Saito N; Itoh K
Int J Cancer; 2000 Nov; 88(4):633-9. PubMed ID: 11058882
[TBL] [Abstract][Full Text] [Related]
2. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
[TBL] [Abstract][Full Text] [Related]
3. Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases.
Imai N; Harashima N; Ito M; Miyagi Y; Harada M; Yamada A; Itoh K
Int J Cancer; 2001 Oct; 94(2):237-42. PubMed ID: 11668504
[TBL] [Abstract][Full Text] [Related]
4. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
5. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
6. Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors.
Nonaka Y; Tsuda N; Shichijo S; Ito M; Maeda Y; Harada M; Kamura T; Shigemori M; Itoh K
Tissue Antigens; 2002 Oct; 60(4):319-27. PubMed ID: 12472661
[TBL] [Abstract][Full Text] [Related]
7. Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients.
Suefuji Y; Sasatomi T; Shichijo S; Nakagawa S; Deguchi H; Koga T; Kameyama T; Itoh K
Br J Cancer; 2001 Apr; 84(7):915-9. PubMed ID: 11286471
[TBL] [Abstract][Full Text] [Related]
8. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides.
Murayama K; Kobayashi T; Imaizumi T; Matsunaga K; Kuramoto T; Shigemori M; Shichijo S; Itoh K
J Immunother; 2000; 23(5):511-8. PubMed ID: 11001544
[TBL] [Abstract][Full Text] [Related]
9. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Seki N; Hoshino T; Kikuchi M; Hayashi A; Itoh K
Cell Immunol; 1997 Feb; 175(2):101-10. PubMed ID: 9023415
[TBL] [Abstract][Full Text] [Related]
10. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
11. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells.
Tomita Y; Harao M; Senju S; Imai K; Hirata S; Irie A; Inoue M; Hayashida Y; Yoshimoto K; Shiraishi K; Mori T; Nomori H; Kohrogi H; Nishimura Y
Cancer Sci; 2011 Jan; 102(1):71-8. PubMed ID: 21087352
[TBL] [Abstract][Full Text] [Related]
12. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K
Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460
[TBL] [Abstract][Full Text] [Related]
13. HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer.
Hoshino T; Seki N; Kikuchi M; Kuramoto T; Iwamoto O; Kodama I; Koufuji K; Takeda J; Itoh K
Int J Cancer; 1997 Mar; 70(6):631-8. PubMed ID: 9096641
[TBL] [Abstract][Full Text] [Related]
14. Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2).
Yoshimura S; Tsunoda T; Osawa R; Harada M; Watanabe T; Hikichi T; Katsuda M; Miyazawa M; Tani M; Iwahashi M; Takeda K; Katagiri T; Nakamura Y; Yamaue H
PLoS One; 2014; 9(1):e85267. PubMed ID: 24416375
[TBL] [Abstract][Full Text] [Related]
15. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
[TBL] [Abstract][Full Text] [Related]
16. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
[TBL] [Abstract][Full Text] [Related]
17. ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients.
Shichijo S; Ishihara Y; Azuma K; Komatsu N; Higashimoto N; Ito M; Nakamura T; Ueno T; Harada M; Itoh K
Oncol Rep; 2005 May; 13(5):907-13. PubMed ID: 15809757
[TBL] [Abstract][Full Text] [Related]
18. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
19. Expression of the SART3 antigens in oral cancers.
Fukuda K
Kurume Med J; 2001; 48(1):55-8. PubMed ID: 11402621
[TBL] [Abstract][Full Text] [Related]
20. Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design.
Zhang J; Yang J; Fan D; Tao H; Wang H; Yu T
Oncol Rep; 2013 May; 29(5):1955-61. PubMed ID: 23503586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
